As there has been no STAT3-targeted drug approved for clinical application, natural products which inhibit STAT3 to achieve the cytotoxic activity in breast cancer studies could be selected as a positive control, such as JSI124 (cucurbitacin I). This evidence concerns the gene STAT3 and breast carcinoma.